Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/19192
Title: Management of Early Node-Positive Breast Cancer in Australia: A Multicentre Study.
Austin Authors: Gannan, Emma;Khoo, Jeremy;Nightingale, Sophie;Suhardja, Thomas Surya;Lippey, Jocelyn;Keane, Holly;Tan, Kian Jin;Clouston, David;Gorelik, Alexandra;Mann, Gregory Bruce
Affiliation: Department of Surgery, Austin Health, Heidelberg, Victoria, Australia
Department of Surgery, The University of Melbourne, Parkville, Victoria, Australia
Department of Surgery, The Royal Melbourne Hospital, Parkville, Victoria, Australia
Department of Surgery, The Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia
Department of Surgery, Monash Medical Centre, Clayton, Victoria, Australia
Department of Surgery, The Alfred Hospital, Melbourne, Victoria, Australia
Department of Surgery, St Vincent's Hospital Melbourne, Fitzroy, Victoria, Australia
Focus Pathology, East Melbourne, Victoria, Australia
Melbourne EpiCentre, The Royal Melbourne Hospital, The University of Melbourne, Parkville, Victoria, Australia
The Breast Service, The Royal Melbourne Hospital & The Royal Women's Hospital, Parkville, Victoria, Australia
Issue Date: Jul-2016
metadata.dc.date: 2016-04-20
Publication information: The breast journal 2016; 22(4): 413-419
Abstract: To examine practice patterns for breast cancer patients with limited sentinel node (SN) disease in light of the ACOSOG Z0011 results. Retrospective analysis of patients with T1-2 breast cancer and positive sentinel lymph node biopsy (SLNB) admitted between January 2009 and December 2012. Patient demographics, tumor characteristics, and treatments were recorded. Eight hundred positive SLNBs were identified. A total of 452 (56.5%) proceeded to completion axillary lymph node dissection (cALND). cALND rate decreased from 65.1% to 49.7% from 2009-2010 to 2011-2012. cALND was performed for micrometastasis or isolated tumor cells in 39.3% in 2009-2010 and 22.2% in 2011-2012, whereas for macrometastases the rates were 83.1% and 68.6%, respectively. cALND rates diminished for both Z0011-eligible and -ineligible patients. The ACOSOG Z0011 trial presentation and publication coincided with a reduction in cALND for breast cancer with limited nodal disease. There appears equipoise regarding management of macrometastatic SN disease.
URI: http://ahro.austin.org.au/austinjspui/handle/1/19192
DOI: 10.1111/tbj.12595
PubMed URL: 27095381
Type: Journal Article
Subjects: ACOSOG Z0011 trial
axillary lymph node dissection
breast cancer
sentinel lymph node biopsy
Appears in Collections:Journal articles

Show full item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.